- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
11 result(s) found for: Rett syndrome.
Displaying page 1 of 1.
EudraCT Number: 2008-000787-16 | Sponsor Protocol Number: C07-22 | Start Date*: 2008-06-12 | |||||||||||
Sponsor Name:Inserm | |||||||||||||
Full Title: Etude pilote ouverte de l'effet de la fluoxetine chez des patientes agées de 8 à 28 ans atteintes du Syndrôme de Rett Typique | |||||||||||||
Medical condition: Sydrome de Rett typique | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004345-32 | Sponsor Protocol Number: ANAVEX2-73-RS-002 | Start Date*: 2020-05-26 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome | |||||||||||||
Medical condition: Rett Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001605-24 | Sponsor Protocol Number: GWND19002 | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome | |||||||||||||
Medical condition: Rett syndrome (RTT) [typical or atypical] | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003370-27 | Sponsor Protocol Number: GWND18064 | Start Date*: 2019-04-09 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. | |||||||||||||
Medical condition: Rett syndrome (RTT) [typical or atypical] | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004448-20 | Sponsor Protocol Number: Sarizotan/001/II/2015 | Start Date*: 2016-11-28 | |||||||||||
Sponsor Name:Newron Pharmaceuticals S.p.A. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms | |||||||||||||
Medical condition: Rett syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006739-30 | Sponsor Protocol Number: 2007-37 | Start Date*: 2008-07-31 |
Sponsor Name:Assistance Publique Hopitaux de marseille | ||
Full Title: etude pilote des effets de la désipramine sur les parametres neurovégétatifs de l'enfant porteur de syndrome de rett | ||
Medical condition: la maladie de syndrome de Rett, | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005021-76 | Sponsor Protocol Number: OPBGC&RS_12_003 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:EDISON PHARMACEUTICALS INC. | |||||||||||||
Full Title: A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome | |||||||||||||
Medical condition: Rett Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005571-10 | Sponsor Protocol Number: 03-08-21-12 | Start Date*: Information not available in EudraCT |
Sponsor Name:Kennedy Krieger Inst. Johns Hopkins Medicine | ||
Full Title: DEXTROMETORPHAN IN RETT SYNDROME | ||
Medical condition: Rett syndrome (RTT) is a neurological disorder with devastating consequences on the brain. It is characterized by stagnation of development followed by regression, both occurring between age 6 mont... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004420-30 | Sponsor Protocol Number: CL3-95008-002 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005534-15 | Sponsor Protocol Number: PRO-GLY-002/E2013 | Start Date*: 2021-04-01 |
Sponsor Name:Proveca Pharma LTD | ||
Full Title: Double-blind, placebo-controlled, randomized clinical trial comparing the efficacy and safety of Sialanar plus oral rehabilitation against placebo plus oral rehabilitation for children and adolesce... | ||
Medical condition: Severe sialorrhoea and neurodisabilties in children | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
